The effects of an individualized smartphone-based exercise program on self-defined motor tasks in Parkinson's disease: a long-term feasibility study.
Journal
Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688
Informations de publication
Date de publication:
30 Oct 2023
30 Oct 2023
Historique:
received:
01
03
2023
accepted:
28
08
2023
medline:
1
11
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
epublish
Résumé
Exercise therapy is considered effective for the treatment of motor impairment in patients with Parkinson's disease (PD). During the COVID-19 pandemic, training sessions were cancelled and the implementation of telerehabilitation concepts became a promising solution. The aim of this controlled interventional feasibility study was to evaluate the long-term acceptance and to explore initial effectiveness of a digital, home-based, high-frequency exercise program for PD patients. Training effects were assessed using patient-reported outcome measures combined with sensor-based and clinical scores. 16 PD patients (smartphone group, SG) completed a home-based, individualized training program over 6-8 months using a smartphone app, remotely supervised by a therapist, and tailored to the patient's motor impairments and capacity. A control group (CG, n = 16) received medical treatment without participating in digital exercise training. The usability of the app was validated using System Usability Scale (SUS) and User Version of the Mobile Application Rating Scale (uMARS). Outcome measures included among others Unified Parkinson Disease Rating Scale, part III (UPDRS-III), sensor-based gait parameters derived from standardized gait tests, Parkinson's Disease Questionnaire (PDQ-39), and patient-defined motor activities of daily life (M-ADL). Exercise frequency of 74.5% demonstrated high adherence in this cohort. The application obtained 84% in SUS and more than 3.5/5 points in each subcategory of uMARS, indicating excellent usability. The individually assessed additional benefit showed at least 6 out of 10 points (Mean = 8.2 ± 1.3). From a clinical perspective, patient-defined M-ADL improved for 10 out of 16 patients by 15.5% after the training period. The results of the UPDRS-III remained stable in the SG while worsening in the CG by 3.1 points (24%). The PDQ-39 score worsened over 6-8 months by 83% (SG) and 59% (CG) but the subsection mobility showed a smaller decline in the SG (3%) compared to the CG (77%) without reaching significance level for all outcomes. Sensor-based gait parameters remained constant in both groups. Long-term training over 6-8 months with the app is considered feasible and acceptable, representing a cost-effective, individualized approach to complement dopaminergic treatment. This study indicates that personalized, digital, high-frequency training leads to benefits in motor sections of ADL and Quality of Life.
Sections du résumé
BACKGROUND
BACKGROUND
Exercise therapy is considered effective for the treatment of motor impairment in patients with Parkinson's disease (PD). During the COVID-19 pandemic, training sessions were cancelled and the implementation of telerehabilitation concepts became a promising solution. The aim of this controlled interventional feasibility study was to evaluate the long-term acceptance and to explore initial effectiveness of a digital, home-based, high-frequency exercise program for PD patients. Training effects were assessed using patient-reported outcome measures combined with sensor-based and clinical scores.
METHODS
METHODS
16 PD patients (smartphone group, SG) completed a home-based, individualized training program over 6-8 months using a smartphone app, remotely supervised by a therapist, and tailored to the patient's motor impairments and capacity. A control group (CG, n = 16) received medical treatment without participating in digital exercise training. The usability of the app was validated using System Usability Scale (SUS) and User Version of the Mobile Application Rating Scale (uMARS). Outcome measures included among others Unified Parkinson Disease Rating Scale, part III (UPDRS-III), sensor-based gait parameters derived from standardized gait tests, Parkinson's Disease Questionnaire (PDQ-39), and patient-defined motor activities of daily life (M-ADL).
RESULTS
RESULTS
Exercise frequency of 74.5% demonstrated high adherence in this cohort. The application obtained 84% in SUS and more than 3.5/5 points in each subcategory of uMARS, indicating excellent usability. The individually assessed additional benefit showed at least 6 out of 10 points (Mean = 8.2 ± 1.3). From a clinical perspective, patient-defined M-ADL improved for 10 out of 16 patients by 15.5% after the training period. The results of the UPDRS-III remained stable in the SG while worsening in the CG by 3.1 points (24%). The PDQ-39 score worsened over 6-8 months by 83% (SG) and 59% (CG) but the subsection mobility showed a smaller decline in the SG (3%) compared to the CG (77%) without reaching significance level for all outcomes. Sensor-based gait parameters remained constant in both groups.
CONCLUSIONS
CONCLUSIONS
Long-term training over 6-8 months with the app is considered feasible and acceptable, representing a cost-effective, individualized approach to complement dopaminergic treatment. This study indicates that personalized, digital, high-frequency training leads to benefits in motor sections of ADL and Quality of Life.
Identifiants
pubmed: 37902922
doi: 10.1186/s41687-023-00631-6
pii: 10.1186/s41687-023-00631-6
pmc: PMC10616049
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106Subventions
Organisme : European Union's Horizon 2020 research and innovation program
ID : 820820
Organisme : European Federation of Pharmaceutical Industries and Associations
ID : 820820
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB 1483-Project-ID 442419336
Organisme : Mobility APP
ID : 438496663
Organisme : Fraunhofer Internal Programs
ID : 044-602140
Organisme : Fraunhofer Internal Programs
ID : 044-602150
Informations de copyright
© 2023. The Author(s).
Références
Front Rehabil Sci. 2022 Feb 24;3:811465
pubmed: 36188988
J Parkinsons Dis. 2021;11(4):1619-1630
pubmed: 34366377
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
J Parkinsons Dis. 2020;10(4):1763-1773
pubmed: 32925099
Lancet Neurol. 2021 May;20(5):385-397
pubmed: 33894193
Public Health Rep. 2009 Sep-Oct;124(5):692-701
pubmed: 19753947
JMIR Mhealth Uhealth. 2020 Oct 5;8(10):e18985
pubmed: 33016887
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S60-4
pubmed: 26360239
Mov Disord. 2020 Apr;35(4):523-536
pubmed: 31799734
IEEE Trans Neural Syst Rehabil Eng. 2021;29:2103-2111
pubmed: 34633932
Rev Neurol. 2020 Mar 1;70(5):161-170
pubmed: 32100276
Neurology. 2022 Jun 6;:
pubmed: 35667840
Neurorehabil Neural Repair. 2020 Oct;34(10):871-880
pubmed: 32917125
Mov Disord. 2020 Jun;35(6):905-908
pubmed: 32347572
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
Parkinsonism Relat Disord. 2020 Nov;80:148-151
pubmed: 33002722
J Formos Med Assoc. 2016 Sep;115(9):734-43
pubmed: 26279172
Front Neurol. 2019 Jan 22;10:5
pubmed: 30723450
Mov Disord Clin Pract. 2018 Jun 26;5(4):448-450
pubmed: 30838303
Lancet Neurol. 2014 Jun;13(6):557-66
pubmed: 24726066
JAMA Neurol. 2018 Feb 1;75(2):219-226
pubmed: 29228079
J Neurol Phys Ther. 2013 Jun;37(2):85-90
pubmed: 23632452
Mov Disord. 2013 Sep 15;28(11):1587-96
pubmed: 24132847
Health Expect. 2019 Oct;22(5):939-951
pubmed: 31199574
Parkinsonism Relat Disord. 2014 Nov;20(11):1221-5
pubmed: 25258329
Arch Neurol. 2010 Jan;67(1):64-70
pubmed: 20065131
Neurology. 2022 Feb 22;98(8):e859-e871
pubmed: 35022304
Mov Disord Clin Pract. 2018 Jan-Feb;5(1):47-53
pubmed: 29662921
Mov Disord. 2006 Aug;21(8):1200-7
pubmed: 16673410
Mov Disord. 2007 Mar 15;22(4):451-60; quiz 600
pubmed: 17133526
IEEE Trans Biomed Eng. 2015 Apr;62(4):1089-97
pubmed: 25389237
J Neurol. 2021 Dec;268(12):4415-4421
pubmed: 34313818
Sensors (Basel). 2015 Mar 17;15(3):6419-40
pubmed: 25789489
Qual Manag Health Care. 2009 Oct-Dec;18(4):247-56
pubmed: 19851232
J Neurol Phys Ther. 2019 Oct;43(4):224-232
pubmed: 31517749
Front Aging Neurosci. 2021 Nov 30;13:722830
pubmed: 34916920
JMIR Rehabil Assist Technol. 2022 Nov 15;9(4):e38994
pubmed: 36378510
CNS Neurosci Ther. 2021 Mar;27(3):270-279
pubmed: 33372386
JMIR Mhealth Uhealth. 2019 May 1;7(5):e13019
pubmed: 31066712
Age Ageing. 2005 Nov;34(6):614-9
pubmed: 16267188
Complement Ther Med. 2019 Feb;42:119-124
pubmed: 30670228
JMIR Res Protoc. 2016 Aug 26;5(3):e172
pubmed: 27565186
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
JAMA. 2020 Feb 11;323(6):548-560
pubmed: 32044947
Mov Disord Clin Pract. 2020 Aug 17;7(7):797-802
pubmed: 32837960
PLoS One. 2013;8(2):e56956
pubmed: 23431395
Int Rev Neurobiol. 2019;147:1-44
pubmed: 31607351
Acad Med. 2017 Feb;92(2):157-160
pubmed: 27119325
J Eval Clin Pract. 2020 Apr;26(2):524-540
pubmed: 31840346
J Physiother. 2019 Oct;65(4):189-199
pubmed: 31521554
Am J Phys Med Rehabil. 2019 Jul;98(7):613-621
pubmed: 30844920
Front Neurol. 2017 Oct 26;8:550
pubmed: 29123499
BMJ. 2015 Feb 10;350:g7818
pubmed: 25670183
JMIR Mhealth Uhealth. 2016 Jun 10;4(2):e72
pubmed: 27287964
J Parkinsons Dis. 2018;8(s1):S3-S8
pubmed: 30584159
Phys Ther. 2012 Nov;92(11):1395-410
pubmed: 22822237
Parkinsonism Relat Disord. 2019 Oct;67:60-65
pubmed: 31621609
Lancet Neurol. 2019 Nov;18(11):998-1008
pubmed: 31521532
Semin Neurol. 2021 Apr;41(2):189-205
pubmed: 33742432
BMC Pediatr. 2011 Jan 12;11:3
pubmed: 21226913
J Mov Disord. 2020 May;13(2):105-114
pubmed: 32344993
Age Ageing. 1997 Sep;26(5):353-7
pubmed: 9351479
Sensors (Basel). 2017 Jun 28;17(7):
pubmed: 28657587
J Parkinsons Dis. 2018;8(s1):S95-S100
pubmed: 30584167
J Parkinsons Dis. 2021;11(s1):S5-S10
pubmed: 33682728
Nat Rev Dis Primers. 2021 Jul 1;7(1):47
pubmed: 34210995